Related Experiment Video
Updated: Feb 6, 2026
05:51
Coculture Analysis of Extracellular Protein Interactions Affecting Insulin Secretion by Pancreatic Beta Cells
Published on: June 15, 2013
13.4K
Characterizing the interaction between insulin-like growth factor 2 mRNA-binding protein 1 (IMP1) and KRAS expression
Sebastian Mackedenski1, Chuyi Wang1, Wai-Ming Li1
1Chemistry Program, University of Northern British Columbia, Prince George, British Columbia, Canada V2N 4Z9.
The Biochemical Journal
|August 15, 2018
Summary
Insulin-like growth factor 2 mRNA-binding protein-1 (IMP1) regulates KRAS. Antisense oligonucleotides targeting IMP1 reduced IMP1 protein, not KRAS, indicating IMP1
Area of Science:
- Molecular Biology
- Cancer Research
- Gene Regulation
Background:
- Insulin-like growth factor 2 mRNA-binding protein-1 (IMP1) interacts with KRAS mRNA.
- IMP1's role in regulating KRAS expression is not fully understood.
- Understanding this interaction is crucial for cancer therapeutics.
Purpose of the Study:
- To characterize the molecular interaction between IMP1 and KRAS mRNA.
- To investigate the effect of antisense oligonucleotides (AONs) on IMP1-KRAS interaction and KRAS expression.
- To elucidate the mechanism by which IMP1 regulates KRAS.
Main Methods:
- Point mutations in IMP1 KH domains to assess RNA binding.
- Mapping of IMP1 binding sites on KRAS mRNA.
- In vitro and in vivo studies using antisense oligonucleotides (SM6, SM7) and siRNA in SW480 colon cancer cells.
- Luciferase reporter assays to study translation regulation.
Main Results:
- All KH domains of IMP1 are critical for KRAS RNA binding.
- IMP1 binds KRAS mRNA with highest affinity to nts 1-185, but also to other regions.
- SM6 and SM7 AONs inhibited IMP1 protein expression without affecting KRAS, suggesting IMP1 translation inhibition.
- Knockdown of IMP1 reduced KRAS expression, confirming IMP1's regulatory role.
- IMP1 translation was significantly reduced by SM7, independent of let-7a levels.
Conclusions:
- IMP1's regulation of KRAS is complex, involving both IMP1 protein and its mRNA.
- Antisense oligonucleotides targeting IMP1 can inhibit IMP1 protein expression.
- Further research is needed to fully understand the IMP1-KRAS regulatory network in cancer.
Related Concept Videos
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
607
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
607
02:51mRNA Stability and Gene Expression
6.7K
The structure and stability of mRNA molecules regulates gene expression, as mRNAs are a key step in the pathway from gene to protein. In eukaryotes, the half-life of mRNA varies from a few minutes up to several days. mRNA stability is essential in growth and development. The absence of the proteins regulating its stability, such as tristetraprolin in mice, can cause systemic issues, including bone marrow overgrowth, inflammation, and autoimmunity.
Cis-acting Elements involved in mRNA stability
Cis-acting Elements involved in mRNA stability
6.7K
02:51mRNA Stability and Gene Expression
3.5K
3.5K
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
574
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
574
01:18Factors Affecting Protein-Drug Binding: Drug-Related Factors
487
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
487
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
327
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
327